AtriCure (ATRC) Stock Slides Despite Strong Earnings Report

Despite delivering strong earnings results and exceeding guidance, AtriCure's stock declined in Q1 2026. Riverwater Partners highlighted the underperformance of ATRC amid broader market volatility driven by geopolitical tensions and sector-specific concerns.

By Soumya Eswaran Tue, May 5, 2026 at 6:20 PM GMT+3 3 min read · Yahoo Finance · May 5, 2026, 15:20 UTC

AtriCure (ATRC) Stock Slides Despite Strong Earnings Report

Tickers: $ATRC

Topics: atrial fibrillation medical devices stock performance

Read the full article at Yahoo Finance

More World news

Apple to Update HomeView Software Following Feedback on Voice Command Limitations The Verge · November 12, 2026, 16:53 UTC
Endeavour Mining Shares Drop Following Production Warning at Mana Gold Mine Seeking Alpha · November 12, 2026, 16:48 UTC
Stellantis CEO Warns of Multi-Billion Euro Impact from Chip Shortages and Raw Material Costs Seeking Alpha · November 12, 2026, 16:44 UTC
UBS Upgrades Rivian to Buy Rating Amid R2 Potential Motley Fool · November 12, 2026, 16:45 UTC
Stifel Downgrades EVgo to Hold Amid Weakening Growth Outlook Seeking Alpha · November 12, 2026, 16:41 UTC
Rowan Digital Infrastructure Secures Over $1.5 Billion in New Financing Seeking Alpha · November 12, 2026, 16:42 UTC
CAE Reports Q2 2027 Results with Increased EPS Guidance and Strong Defense Growth Motley Fool · November 12, 2026, 16:39 UTC
Alvotech Reports Q3 2026 Financial Results Amid Manufacturing Recovery Motley Fool · November 12, 2026, 16:39 UTC
Jacobs Solutions Declares Quarterly Dividend of $0.36 Per Share Seeking Alpha · November 12, 2026, 16:39 UTC
SOLV Energy Raises Revenue Guidance Following Record Q3 Project Execution Seeking Alpha · November 12, 2026, 16:40 UTC